Sílvia Vilarinho

Sílvia Vilarinho

Auto-generated profile, based on publicly available information

Sílvia Vilarinho

Departments of Internal Medicine (Section of Digestive Diseases), Genetics and Pathology, Yale School of Medicine, New Haven, Connecticut, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2022 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
MVMarijana Vujkovic
Marijana Vujkovic
SRShweta Ramdas
Shweta Ramdas
KLKim M. Lorenz
Kim M. Lorenz
XGXiuqing Guo
Xiuqing Guo
RDRebecca Darlay
Rebecca Darlay
KCKyong-Mi Chang
Kyong-Mi Chang

28 June 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MOMasato Ogishi
Masato Ogishi
RYRui Yang
Rui Yang
CACaner Aytekin
Caner Aytekin
DLDavid Langlais
David Langlais
MBMathieu Bourgey
Mathieu Bourgey
JCJean-Laurent Casanova
Jean-Laurent Casanova

19 September 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SVSílvia Vilarinho
Sílvia Vilarinho
SSSinan Sari
Sinan Sari
FMFrancesca Mazzacuva
Francesca Mazzacuva
KBKaya Bilgüvar
Kaya Bilgüvar
GEGüldal Esendagli-Yilmaz
Güldal Esendagli-Yilmaz
RLRichard P. Lifton
Richard P. Lifton
Significance: Liver disease of unknown cause represents an unmet medical need. Using exome sequencing, we describe a syndrome associated with homozygous loss of Acyl CoA Oxidase 2 ( ACOX2 ) featuring elevated transaminase levels, liver fibrosis, ataxia, and cognitive impairment. ACOX2 encodes the peroxisomal branched-chain acyl-CoA oxidase and is involved in the bile acid biosynthetic pathway. Importantly, this disorder is potentially reversible, because the bile acid synthetic pathway can be suppressed with exogenous bile acids, diminishing the production of the toxic metabolites likely causing liver and neurologic dysfunction. This study provides the means to diagnose ACOX2 deficiency in patients with chronic idiopathic liver disease and/or cryptogenic cirrhosis.

17 April 2024 in Nature Genetics
Verified
Journal Article
Open access
PDF file
JGJonas Ghouse
Jonas Ghouse
GSGardar Sveinbjörnsson
Gardar Sveinbjörnsson
MVMarijana Vujkovic
Marijana Vujkovic
ASAnne-Sofie Seidelin
Anne-Sofie Seidelin
HGHelene Gellert-Kristensen
Helene Gellert-Kristensen
SSStefan Stender
Stefan Stender
We report a multi-ancestry genome-wide association study on liver cirrhosis and its associated endophenotypes, alanine aminotransferase (ALT) and γ-glutamyl transferase. Using data from 12 cohorts, including 18,265 cases with cirrhosis, 1,782,047 controls, up to 1 million individuals with liver function tests and a validation cohort of 21,689 cases and 617,729 controls, we identify and validate 14 risk associations for cirrhosis. Many variants are located near genes involved in hepatic lipid metabolism. One of these, PNPLA3 p.Ile148Met, interacts with alcohol intake, obesity and diabetes on the risk of cirrhosis and hepatocellular carcinoma (HCC). We develop a polygenic risk score that associates with the progression from cirrhosis to HCC. By focusing on prioritized genes from common variant analyses, we find that rare coding variants in GPAM associate with lower ALT, supporting GPAM as a potential target for therapeutic inhibition. In conclusion, this study provides insights into the genetic underpinnings of cirrhosis.

24 September 2021 in Hepatology
Verified
Journal Article
Closed access
SVSílvia Vilarinho
Sílvia Vilarinho
VAVeeral Ajmera
Veeral Ajmera
MZMelanie Zheng
Melanie Zheng
RLRohit Loomba
Rohit Loomba

1 June 2019 in Journal of Hepatology
Verified
Journal Article
Closed access
AHAaron Hakim
Aaron Hakim
XZXuchen Zhang
Xuchen Zhang
ADAngela DeLisle
Angela DeLisle
EOElif A. Oral
Elif A. Oral
DDDaniel Dykas
Daniel Dykas
SVSilvia Vilarinho
Silvia Vilarinho